Your browser doesn't support javascript.
loading
Nuevas armas inmunológicas para la medicina del siglo XXI: Terapia biológica basada en el uso de anticuerpos monoclonales de última generación / New immunological weapons for Medicine at XXI century: biological therapy based on the use of last generation monoclonal antibodies
Aguillón G, Juan C; Contreras L, Juan; Dotte G, André; Cruzat C, Andrea; Catalán M, Diego; Salazar A, Lorena; Molina S, María Carmen; Guerrero P, Julia; López N, Mercedes.
  • Aguillón G, Juan C; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Contreras L, Juan; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Dotte G, André; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Cruzat C, Andrea; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Catalán M, Diego; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Salazar A, Lorena; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Molina S, María Carmen; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • Guerrero P, Julia; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
  • López N, Mercedes; Universidad de Chile. Facultad de Medicina. Instituto de Ciencias Biomédicas. Programa Disciplinario de Inmunología. Santiago. CL
Rev. méd. Chile ; 131(12): 1445-1453, dic. 2003. tab
Article in Spanish | LILACS | ID: lil-360244
ABSTRACT
The fusion of a murine B cell and a myeloma cell generates a hybridoma that produces monoclonal antibody (mAb). These murine mAb induce the HAMA (human anti-mouse antibodies) response. Murine mAb have been modified by genetic engineering, producing molecules with a higher proportion of human protein. At present, chimeric, humanized and fully human mAb are available. mAb block interactions between target molecules and their ligands or trigger the lyses of mAb-coated tumor cells. Numerous mAb have been developed using the recombinant DNA technology and several are available in the market. Trastuzumab, against HER2/neu, is useful in breast cancer; rituximab, against CD20 in B lymphocytes is useful in lymphoma; alemtuzumab, against CD52 is used in lymphoma and leukemia; daclizumab and basiliximab block the IL-2 receptor interaction and reduce acute rejection in kidney transplantion; abciximab, an antagonist of GPIIb/IIIa platelet receptor, is used in patients undergoing acute coronary syndromes. In autoimmunity diseases, blocking tumor necrosis factor by infliximab and adalimumab has demonstrated excellent results. Thus, infliximab is useful in the treatment of rheumatoid arthritis (RA), Crohn's disease and ulcerative colitis while adalimumab is the first fully human mAb available for RA. Infliximab and adalimumab reduce signs and symptoms in RA and they also interfere with progression of joint damage. Finally, the direct benefits of antagonist treatment can occur at the expense of a major adverse effect in some other biological function (Rev Méd Chile 2003; 131 1445-53).
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Biological Therapy / Antibodies, Monoclonal Limits: Animals / Humans Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2003 Type: Article / Project document Affiliation country: Chile Institution/Affiliation country: Universidad de Chile/CL

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Biological Therapy / Antibodies, Monoclonal Limits: Animals / Humans Language: Spanish Journal: Rev. méd. Chile Journal subject: Medicine Year: 2003 Type: Article / Project document Affiliation country: Chile Institution/Affiliation country: Universidad de Chile/CL